Opinion|Videos|January 12, 2024
Impact of Off-Target AEs and Treatment Resistance on Evolving 1L Therapy Strategies for CLL
Javier Pinilla, MD, PhD, provides a brief overview of the changing CLL treatment landscape, discussing the influence of off-target adverse events and the development of treatment resistance on the evolution of BTK inhibitor therapy.
Advertisement
Episodes in this series
Advertisement
Related to this article
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.
The NMPA has approved pirtobrutinib in treatment-naive and previously treated CLL/SLL.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
2
Guardant360 CDx Receives European Approval as Companion Diagnostic for Camizestrant in ESR1-Mutated Advanced Breast Cancer
3
Next-Generation NAMPT Inhibitors Aim to Revive a Stalled Target in AML and MDS
4
Targeted Approaches in Pancreatic Cancer, Chemo Intensification in CRC Take Center Stage as Key GI Oncology Presentations at ESMO 2026
5